Budesonide versus prednisone in the treatment of active Crohn's disease
作者： Simon Bar–Meir , Yehuda Chowers , Alexandra Lavy , Dov Abramovitch , Amos Sternberg
DOI: 10.1016/S0016-5085(98)70254-9
关键词:
摘要: Abstract Background & Aims: Budesonide (BUD) is a potent steroid that undergoes extensive first-pass metabolism. BUD incorporated in pH-dependent formulation has been proposed as an alternative treatment for Crohn's disease (CD). The aim of this study was to compare the efficacy and safety prednisone (PRED) active CD involving terminal ileum and/or colon. Methods: Patients with mild moderately were included randomized, double-blind, double-dummy controlled trial. received either 9 mg once daily 8 weeks or 40 PRED first 2 tapered gradually 5 mg/day by end study. Disease activity, quality life, laboratory parameters recorded. Results: One hundred patients BUD, 101 PRED. By intention-to-treat analysis, defined Activity Index GASTROENTEROLOGY 1998;115:835-840
gastrojournal.org
elsevier.com
sci-hub.se 参考文章(14)
T Andus, J Schölmerich, H Lochs, I Caesar, U Bär, A Weber, M Gierend, K Ewe, H J Schulz, A Tromm, S C Bischoff, V Gross, Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. European Journal of Gastroenterology & Hepatology. ,vol. 8, pp. 905- 909 ,(1996)
Robert W. Summers, Donald M. Switz, John T. Sessions, Jack M. Becktel, William R. Best, Fred Kern, John W. Singleton, National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. ,vol. 77, pp. 847- 869 ,(1979) , 10.1016/0016-5085(79)90385-8
M Campieri, A Ferguson, W Doe, T Persson, L-G Nilsson, , Oral budesonide is as effective as oral prednisolone in active Crohn’s disease Gut. ,vol. 41, pp. 209- 214 ,(1997) , 10.1136/GUT.41.2.209
Caroline M. Spencer, Donna McTavish, Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease Drugs. ,vol. 50, pp. 854- 872 ,(1995) , 10.2165/00003495-199550050-00006
M Nilsson, S Edsbäcker, P Larsson, JE Wirén, Dose-proportional kinetics of budesonide controlled ileal release capsules Gastroenterology. ,vol. 108, pp. A885- ,(1995) , 10.1016/0016-5085(95)27845-1
H. Malchow, K. Ewe, J.W. Brandes, H. Goebell, H. Ehms, H. Sommer, H. Jesdinsky, European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment Gastroenterology. ,vol. 86, pp. 249- 266 ,(1984) , 10.1016/0016-5085(84)90409-8
R Brattsand, Overview of Newer Glucocorticosteroid Preparations for Inflammatory Bowel Disease Canadian Journal of Gastroenterology & Hepatology. ,vol. 4, pp. 407- 414 ,(1990) , 10.1155/1990/708916
Gordon R. Greenberg, Brian G. Feagan, Francois Martin, Lloyd R. Sutherland, Alan Thomson, C. Noel Williams, Lars-Goran Nilsson, Tore Persson, Oral Budesonide for Active Crohn's Disease New England Journal of Medicine. ,vol. 331, pp. 836- 841 ,(1994) , 10.1056/NEJM199409293311303
William R. Best, Jack M. Becktel, John W. Singleton, Fred Kern, Development of a Crohn's Disease Activity Index: National Cooperative Crohn's Disease Study Gastroenterology. ,vol. 70, pp. 439- 444 ,(1976) , 10.1016/S0016-5085(76)80163-1
Paul Rutgeerts, Robert Lofberg, Helmut Malchow, Cornelis Lamers, Gunnar Olaison, Derek Jewell, Ake Danielsson, Harald Goebell, Ole Ostergaard Thomsen, Hertwig Lorenz-Meyer, Humphrey Hodgson, Tore Persson, Cecilia Seidegard, None, A Comparison of Budesonide with Prednisolone for Active Crohn's Disease New England Journal of Medicine. ,vol. 331, pp. 842- 845 ,(1994) , 10.1056/NEJM199409293311304